Novavax (NVAX) to Release Earnings on Wednesday

Novavax (NASDAQ:NVAX) is expected to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Novavax to post earnings of ($0.25) per share and revenue of $78.3220 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.66) by $0.77. Novavax had a negative return on equity of 673.17% and a net margin of 39.19%.The business had revenue of $136.40 million during the quarter, compared to analysts’ expectations of $90.26 million. During the same period in the previous year, the business earned ($0.51) earnings per share. The firm’s revenue was up 66.6% on a year-over-year basis. On average, analysts expect Novavax to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Trading Up 0.8%

Shares of NVAX traded up $0.06 during midday trading on Tuesday, reaching $8.09. The stock had a trading volume of 2,481,510 shares, compared to its average volume of 4,581,160. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of 3.36 and a beta of 2.37. The company’s 50-day moving average is $9.08 and its 200 day moving average is $8.19. Novavax has a 12-month low of $5.80 and a 12-month high of $11.97.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on NVAX. HC Wainwright upped their target price on Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Novavax in a research note on Thursday, March 12th. B. Riley Financial restated a “buy” rating on shares of Novavax in a research report on Thursday, April 9th. Finally, BTIG Research reaffirmed a “buy” rating and set a $19.00 price objective on shares of Novavax in a research note on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $11.88.

Institutional Investors Weigh In On Novavax

Large investors have recently added to or reduced their stakes in the company. State Street Corp raised its stake in shares of Novavax by 32.3% during the fourth quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock valued at $63,999,000 after acquiring an additional 2,326,927 shares during the last quarter. Barclays PLC grew its stake in shares of Novavax by 108.8% in the fourth quarter. Barclays PLC now owns 1,102,300 shares of the biopharmaceutical company’s stock worth $7,407,000 after purchasing an additional 574,263 shares during the last quarter. Jump Financial LLC purchased a new position in Novavax during the 3rd quarter valued at about $3,874,000. HRT Financial LP increased its holdings in Novavax by 191.8% during the 2nd quarter. HRT Financial LP now owns 615,649 shares of the biopharmaceutical company’s stock valued at $3,878,000 after purchasing an additional 404,676 shares during the period. Finally, Thrivent Financial for Lutherans bought a new position in Novavax during the 2nd quarter valued at approximately $1,321,000. Institutional investors own 53.04% of the company’s stock.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.